Zibotentan, Dapagliflozin Combo Further Reduces Albuminuria in CKD

ZENITH-CKD is the first randomized trial comparing combined SGLT2 and endothelin A inhibition in patients with chronic kidney disease. Endothelin system blockade with zibotentan is a potential new therapy in chronic kidney disease (CKD).

Related Keywords

Netherlands ,Edinburgh ,City Of ,United Kingdom ,Philadelphia ,Pennsylvania ,United States ,Groningen ,American ,Gavin Brian Chapman ,Hiddo Lambers Heerspink ,Neeraj Dhaun ,Astrazeneca ,University Of Edinburgh ,Zenith ,University Medical Center Groningen ,American Society Of Nephrology Kidney Week ,American Society ,Kidney Week ,